Drug Trial Radar · NCT04914897
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
106
Actual
Start
Sep 23, 2021
Primary completion
Jul 18, 2023
Study completion Oct 17, 2024
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: * To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. * To assess other indicators of antitumor activity. * To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab. * To assess the immunogenicity of SAR444245.
Conditions
- Pleural Mesothelioma
- Non-small Cell Lung Cancer
Interventions
THOR-707Drug
Intravenous infusion: solution for infusion
PembrolizumabDrug
Intravenous infusion: solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts A1 and A2: Objective Response Rate (ORR)Time frame: From first dose of study treatment administration (Day 1) up to approximately 21 months
- Cohorts B1: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 14 months
- Cohorts C1: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to approximately 21 months
Locations
35 sites in 11 countries. Site status is shown where the registry gives one.
Thomas Jefferson University Hospital Site Number : 8400009
Philadelphia, Pennsylvania
Thomas Jefferson University - North East Site Number : 8401009
Philadelphia, Pennsylvania
Investigational Site Number : 0320002
CABA, Buenos Aires, Argentina
Investigational Site Number : 0360002
Richmond, Victoria, Australia
Investigational Site Number : 1520003
Temuco, Chile
Investigational Site Number : 1520005
Santaigo, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520002
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 2500006
Bordeaux, France
Investigational Site Number : 2500005
Paris, France
Investigational Site Number : 2500001
Saint-Herblain, France
Investigational Site Number : 2500003
Toulouse, France
Investigational Site Number : 3800006
Bologna, Italy
Investigational Site Number : 3800004
Milan, Italy
Investigational Site Number : 3800008
Padova, Italy
Investigational Site Number : 3800005
Aviano (PN), Friuli Venezia Giulia, Italy
Investigational Site Number : 3800001
Rozzano, Milano, Italy
Investigational Site Number : 3800002
Orbassano, Torino, Italy
Investigational Site Number : 3920001
Sapporo, Hokkaido, Japan
Investigational Site Number : 6160002
Poznan, Greater Poland Voivodeship, Poland
Investigational Site Number : 6160001
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6160003
Gdansk, Pomeranian Voivodeship, Poland
Investigational Site Number : 6160004
Olsztyn, Warmian-Masurian Voivodeship, Poland
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100003
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, South Korea
Investigational Site Number : 7240002
Madrid, Spain
Investigational Site Number : 7240001
Madrid, Spain
Investigational Site Number : 7240006
Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240003
Girona, Girona [Gerona], Spain
Investigational Site Number : 7240004
Madrid, Madrid, Comunidad de, Spain
Investigational Site Number : 1580003
Taichung, Taiwan
Investigational Site Number : 1580002
Tainan, Taiwan
Investigational Site Number : 1580005
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.